Comparative Pharmacology
Head-to-head clinical analysis: LIBRELEASE versus TEMAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRELEASE versus TEMAZEPAM.
LIBRELEASE vs TEMAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIBRELEASE is a novel therapeutic agent that modulates neurotransmitter release by binding to presynaptic voltage-gated calcium channels, specifically the alpha-2-delta subunit, thereby reducing calcium influx and subsequent neurotransmitter exocytosis. This results in decreased neuronal excitability and modulation of pain pathways.
Positive allosteric modulator of GABA-A receptors, enhancing the effect of GABA by increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
10 mg once daily, oral, administered in the morning.
10-20 mg orally at bedtime, up to 30 mg in severe insomnia.
None Documented
None Documented
Terminal elimination half-life 12–15 hours in healthy adults; prolonged in renal impairment (up to 30 hours).
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life is 8–20 hours in healthy adults (mean ~15 hours); may be prolonged in elderly (up to 50 hours) and in hepatic impairment (up to 40 hours); clinical context: typical dosing interval is 12–24 hours.
Primarily renal excretion of unchanged drug (60–70%) and hepatic metabolism with biliary/fecal elimination (20–30%).
Renal excretion of conjugated metabolites (primarily as glucuronide) accounts for approximately 80% of an oral dose; fecal excretion accounts for about 12%; less than 1% is excreted unchanged in urine.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."